Merck, Inc.
🇵🇭Philippines
Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)
Phase 3
Completed
- Conditions
- Metastatic Bone SarcomasMetastatic Soft-Tissue Sarcomas
- Interventions
- Drug: PlaceboDrug: ridaforolimus
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 711
- Registration Number
- NCT00538239
Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)
Phase 3
Terminated
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Azathioprine (AZA)Biological: Infliximab (IFX)Drug: Placebo to AzathioprineDrug: Placebo infusion
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 242
- Registration Number
- NCT00537316
A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)
Phase 1
Completed
- Conditions
- Bladder Neoplasms
- Interventions
- Genetic: SCH 721015 with SCH 209702
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 17
- Registration Number
- NCT00536588
Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
Phase 2
Completed
- Conditions
- Brain DiseasesMovement DisordersParkinson DiseaseNeurodegenerative DiseasesCentral Nervous System Diseases
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 140
- Registration Number
- NCT00537017
PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)
Phase 3
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: pegylated interferon alpha-2b
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 671
- Registration Number
- NCT00536263
Effect of MK0524A on Cholesterol Levels (0524A-048)
Phase 3
Completed
- Conditions
- HypercholesterolemiaHyperlipidemia
- Interventions
- Drug: laropiprant/niacin (MK0524A)
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 646
- Registration Number
- NCT00536510
MK0524A Phase IIb Study (0524A-011)(COMPLETED)
Phase 2
Completed
- Conditions
- Flushing
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 154
- Registration Number
- NCT00536237
Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)
Phase 2
Completed
- Conditions
- Anesthesia, General
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 174
- Registration Number
- NCT00535743
Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 91
- Registration Number
- NCT00535496
Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
Phase 3
Completed
- Conditions
- Postmenopausal SymptomsMenopauseVasomotor Symptoms
- Interventions
- Drug: EsmirtazapineDrug: Placebo
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 946
- Registration Number
- NCT00535288
© Copyright 2025. All Rights Reserved by MedPath